Selenium may reduce side effects from cisplatin without reducing the clinical
effectiveness of this medication (Olas and Wachowicz 1997). Administration of
sodium selenite (2 mg/kg) one hour before cisplatin treatment greatly reduced
the nephrotoxic effects associated with the drug but did not alter antitumor
activity (Baldew et al. 1989). The pharmacokinetic parameters of the drug were
also not affected by the combination of radiolabeled sodium selenite and
cisplatin (Vermeulen et al. 1993).
A clinical trial involving 41 patients with ovarian or metastatic endometrial
cancer evaluated the effects of selenium on various cancer treatments (Sundstrom
et al. 1989). Patients were treated with cisplatin in combination with either
doxorubicin and cyclophosphamide or melphalan. In addition, some patients were
supplemented with selenium (200 mcg/day sodium selenate), vitamin E (300
mg/day), or selenium and vitamin E. Selenium supplementation during cisplatin
treatment reduced measures of oxidative stress.
Preclinical studies also suggest that selenium supplementation limits
doxorubicin-induced cardiotoxicity (Boucher et al. 1995; Dimitrov et al. 1987).
Selenium was more effective when given prior to doxorubicin exposure.
Baldew GS, van den Hamer CJ, Los G, et al. Selenium-induced protection
against cis-diamminedichloroplatinum(II) nephrotoxicity in mice and rats.
Cancer Res. 1989;49:3020-3023.
Boucher F, Coudray C, Tirard V, et al. Oral selenium supplementation in rats
reduces cardiac toxicity of adriamycin during ischemia and reperfusion.
Nutr. 1995;11(5 Suppl):708-711.
Dimitrov NV, Hay MB, Siew S, et al. Abrogation of adriamycin-induced
cardiotoxicity by selenium in rabbits. Am J Pathol. 1987;126:376-383.
Olas B, Wachowicz B. Selenium in the cytotoxicity of cisplatin. Postepy
Hig Med Dosw. 1997;51(1):95-108.
Sundstrom H, Korpela H, Sajanti E, et al. Supplementation with selenium,
vitamin E and their combination in gynaecological cancer during cytotoxic
chemotherapy. Carcinog. 1989;10:273-278.
Vermeulen NP, Baldew GS, Los G, et al. Reduction of cisplatin nephrotoxicity
by sodium selenite. Lack of interaction at the pharmacokinetic level of both
compounds. Drug Metab Dispos. 1993;
Copyright © 2000 Integrative Medicine
CommunicationsThis publication contains
information relating to general principles
of medical care that should not in any event be construed as specific
instructions for individual patients. The publisher does not accept any
responsibility for the accuracy of the information or the consequences arising
from the application, use, or misuse of any of the information contained herein,
including any injury and/or damage to any person or property as a matter of
product liability, negligence, or otherwise. No warranty, expressed or implied,
is made in regard to the contents of this material. No claims or endorsements
are made for any drugs or compounds currently marketed or in investigative use.
The reader is advised to check product information (including package inserts)
for changes and new information regarding dosage, precautions, warnings,
interactions, and contraindications before administering any drug, herb, or
supplement discussed herein.